BMS/AstraZeneca post more good news on dapagliflozin
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb/AstraZeneca's first-in-class SGLT2 inhibitor dapagliflozin has passed two more Phase III trials, bringing its total late-stage successes to date up to five. Additional trials are underway, but the companies say they are on track for an EU filing by the end of this year. Filing plans in the US will depend on the results of an ongoing cardiovascular safety assessment for the novel drug.